Skip to content

Trial Summary

A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors

Acronym:

ADG116-1003

ACTRN/NCT /ethics:

NCT04111445

Scientific title:

Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors

Sponsor / Cooperative group:

Adagene Inc

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18+ years
SexBoth
Tumour Stream Breast
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-01-06
Anticipated End Date2021-07-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusNot Yet Recruiting